The relevance of heart failure severity for treatment with evidence-based pharmacotherapy in general practice

LG Pont*, WH van Gilst, DJA Lok, HJA Kragten, FM Haaijer-Ruskamp, Dutch Working Group Heart Failure

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

10 Citaten (Scopus)
221 Downloads (Pure)


Aims: Internationally, research indicates that pharmacotherapy for chronic heart failure (CHF) is sub-optimal. Traditionally, assessment of drug use in heart failure has focused on the use of individual agents irrespective of CHF severity. This study investigates drug use for CHF patients in general practice with respect to the available evidence, incorporating both disease severity and the use of combination drug realines. Methods and results: A cross-sectional survey of 769 Dutch CHF patients was performed as part of IMPROVEMENT of HF study. For each New York Heart Association severity classification the minimum treatment appropriate for the heart failure severity according to the scientific evidence available at the time of the study (1999) was defined. The proportion of patients treated with each drug increased with increasing severity, with the exception of the beta-blockers. Patients with less severe heart failure were approximately four to eight times more likely to receive evidence-based treatment than those with more severe heart failure. Discussion: To assess pharmacological treatment of heart failure, in relation to the available evidence, it is important to take severity into account. While the number of drugs prescribed increased with increasing severity, the use of evidence-based regimes was lower in patients with more severe heart failure, (C) 2002 European Society of Cardiology. Published by Elsevier Science B.V. All rights reserved.

Originele taal-2English
ArtikelnummerPII S1388-9842(02)00202-7
Pagina's (van-tot)187-193
Aantal pagina's7
TijdschriftEuropean Journal of Heart Failure
Nummer van het tijdschrift2
StatusPublished - mrt-2003

Citeer dit